Lele Song1,2, Xiumei Peng3,4, Yuemin Li1, Wenhua Xiao4, Jia Jia1,5, Cheng Dong1, Yuan Gong6, Guangpeng Zhou2, Xiaoliang Han2. 1. Department of Radiotherapy, the Chinese PLA 309th Hospital, Beijing, PR China. 2. BioChain (Beijing) Science & Technology Inc., Beijing, PR China. 3. Medical School of Chinese PLA & Chinese PLA General Hospital, Beijing, PR China. 4. Department of Oncology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, PR China. 5. Department of Graduate, Hebei North University, Zhangjiakou, Hebei, PR China. 6. Department of Gastroenterology, the Chinese PLA General Hospital, Beijing, PR China.
Abstract
AIM: This study validated the detection of colorectal adenoma in opportunistic screening using the SEPT9 gene methylation assay. MATERIALS & METHODS: Plasma samples including 85 colorectal cancers, 364 adenomas, 216 hyperplastic polyps, 372 other gastrointestinal diseases and 324 normal subjects, were obtained and tested using the Epi proColon 2.0 CE assay. RESULTS & CONCLUSION: The SEPT9 assay detected 38.7% of all types of adenoma, including 27.8% of serrated adenoma, 28.7% of tubular adenoma, 53.7% of tubulovillous adenoma and 83.3% of villous adenoma. It also detected 27.5% of nonadvanced adenoma (NAA), 47.0% of advanced adenoma (AA) without high-grade dysplasia and 62.5% of AA with high-grade dysplasia. The average adenoma detection rate was 31.8% (95% CI: 28.3-35.4%) with the Boston Bowel Preparation Scale score at 7.6 ± 1.2 (mean ± SD). Our study provided strong evidence for the application of the SEPT9 assay in AA detection in opportunistic screening.
AIM: This study validated the detection of colorectal adenoma in opportunistic screening using the SEPT9 gene methylation assay. MATERIALS & METHODS: Plasma samples including 85 colorectal cancers, 364 adenomas, 216 hyperplastic polyps, 372 other gastrointestinal diseases and 324 normal subjects, were obtained and tested using the Epi proColon 2.0 CE assay. RESULTS & CONCLUSION: The SEPT9 assay detected 38.7% of all types of adenoma, including 27.8% of serrated adenoma, 28.7% of tubular adenoma, 53.7% of tubulovillous adenoma and 83.3% of villous adenoma. It also detected 27.5% of nonadvanced adenoma (NAA), 47.0% of advanced adenoma (AA) without high-grade dysplasia and 62.5% of AA with high-grade dysplasia. The average adenoma detection rate was 31.8% (95% CI: 28.3-35.4%) with the Boston Bowel Preparation Scale score at 7.6 ± 1.2 (mean ± SD). Our study provided strong evidence for the application of the SEPT9 assay in AA detection in opportunistic screening.
Authors: Sander Bach; Nina R Sluiter; Jamie J Beagan; Joost M Mekke; Johannes C F Ket; Nicole C T van Grieken; Renske D M Steenbergen; Bauke Ylstra; Geert Kazemier; Jurriaan B Tuynman Journal: JNCI Cancer Spectr Date: 2019-06-19